Prevent Kidney Injury; Manage Clarithromycin and Calcium Channel Blocker Interactions
As a clinical pharmacist, you are likely to encounter alerts regarding potential kidney problems when clarithromycin is combined with calcium channel blockers (CCBs) such as Norvasc (amlodipine). Understanding the pharmacokinetic interactions and clinical implications of this combination is crucial for preventing adverse effects in patients, especially the elderly.
- Clarithromycin (Klacid, etc) is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. This inhibition can significantly slow the metabolism of CCBs, leading to elevated levels of these drugs in the bloodstream.
- The increased drug levels can result in adverse effects such as hypotension, peripheral edema, bradycardia, shock and acute kidney injury (AKI) due to reduced renal perfusion.
Studies have shown that for every 465 patients over the age of 65 taking a CCB with clarithromycin instead of azithromycin, one additional patient is hospitalized for AKI. The risk is particularly high with dihydropyridine CCBs like nifedipine (Adalat, etc) and felodipine (Plendil, etc).
To mitigate these risks, consider prescribing azithromycin (Zithromax, etc) or another antibiotic instead of clarithromycin or erythromycin for patients on CCBs, particularly those over 65 years old. If clarithromycin is necessary, such as for the treatment of Helicobacter pylori infection, consider holding the calcium channel blocker or reducing its dose during the antibiotic course.
Additionally, close monitoring of blood pressure (BP) and instructing patients to report any signs of dizziness or edema can help in early detection and management of potential adverse effects.
Take-home points
- Prescribe azithromycin instead of clarithromycin for patients on calcium channel blockers to avoid interactions.
- Consider holding or reducing the dose of calcium channel blockers if clarithromycin is necessary.
- Monitor blood pressure and renal function closely in patients taking both medications.
- Advise patients to report symptoms like dizziness or edema promptly.
References
- Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544-2553. doi:10.1001/jama.2013.282426
- Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011;183(3):303-307. doi:10.1503/cmaj.100702
- Mendu ML, Waikar SS. Drug-drug interactions and acute kidney injury: caveat prescriptor. Am J Kidney Dis. 2014 Oct;64(4):492-4. doi: 10.1053/j.ajkd.2014.04.015
Keywords: Clarithromycin and calcium channel blockers, Drug interaction prevention, Acute kidney injury risk, Medication safety tips, Elderly patient care, Clinical pharmacy best practices, Blood pressure monitoring, Hypotension management, Pharmacotherapy guidelines, Clarithromycin alternatives
Join the conversation